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Abstract
Background and objective: The CYP2C19*2 allele is associated with reduced clopidogrel bioactivation, increasing 
the risk of complications after percutaneous coronary intervention (PCI), particularly stent thrombosis. Recently 
published data suggests that CYP2C19*2 allele carriers have a higher risk for in-stent restenosis (ISR) after en-
dovascular treatment. Very few studies have investigated the relationship between CYP2C19*2 and coronary 
ISR, with no significant association reported. The objective of this study was to assess the relationship between 
CYP2C19*2 allele carrier status and coronary ISR.
Methods: Patients with previous PCI with stenting and who were scheduled for elective PCI after coronary angio-
gram were recruited from the cardiac catheterization suite over a 12-month period. The angiography report of 
each patient was perused to identify patients requiring PCI due to ISR. For patients with angiography-confirmed 
ISR, date of previous PCI to the restenosed stent was noted. CYP2C19*2 genotyping was undertaken using a 
TaqMan® Drug Metabolism assay. The association between CYP2C19*2 allele carrier status and incidence of coro-
nary ISR within 1 year was assessed using Fisher’s exact test (p < 0.05 significance) and by calculating the odds 
ratio (OR) with a 95% confidence interval (CI).
Results: Of the 82 patients with previous PCI, 29 (35.4%) had angiography-confirmed ISR (12 carriers, 17 non-
carriers of CYP2C19*2). In 13 (44.8%) of these patients, the restenosed stent was deployed within 1 year and the 
patients were on clopidogrel therapy at the time of repeat PCI (8 carriers, 5 non-carriers of CYP2C19*2). The as-
sociation between CYP2C19*2 allele carrier status and ISR within 1 year was not statistically significant (Fisher’s 
exact p = 0.067; OR: 4.80, 95% CI: 0.98–23.54, p = 0.053).
Conclusions: Despite a higher proportion of CYP2C19*2 allele carriers exhibiting ISR within 1 year compared to 
non-carriers, the association was not statistically significant. This result may be attributed to the small sample 
size, and larger prospective studies are recommended to further assess this association.
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Introduction
Dual antiplatelet therapy with aspirin and a P2Y12 receptor inhibi-
tor is the standard treatment for patients undergoing percutaneous 
coronary intervention (PCI) with stent deployment to reduce the 
risk of post-procedural thrombotic complications. This synergistic 
combination therapy is typically given for 3 months after PCI for 
bare metal stents (BMS) and for at least 1 year with drug-eluting 
stents (DES).1–3 Whilst European guidelines tend to favor use of 
the newer P2Y12 receptor inhibitors prasugrel and ticagrelor as 
first-line agents, provided there is no high risk of bleeding2, Ameri-
can guidelines recommend these newer antiplatelet agents as po-
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tential alternatives to clopidogrel.3 Clopidogrel is still the most 
extensively used P2Y12 receptor inhibitor after PCI, particularly 
due to more robust evidence, lower cost and decreased incidence 
of bleeding compared to the newer P2Y12 receptor inhibitors.4
Clopidogrel is a thienopyridine inactive prodrug and requires 
biotransformation in the liver to form its pharmacologically ac-
tive metabolite, which selectively and irreversibly antagonizes the 
P2Y12 component of the adenosine diphosphate receptor on the 
platelet surface and consequently attenuates platelet aggregation.5 
Two sequential hepatic oxidative steps are involved in clopidogrel 
metabolism to the active metabolite,5 with cytochrome P (CYP) 
450 2C19 being the principal enzyme involved in both steps.6 The 
CYP2C19 enzyme is encoded by a highly polymorphic gene and 
CYP2C19 single nucleotide polymorphisms have been identified 
as significantly and consistently associated with variability in 
clopidogrel response.6–9
The *2 variant allele is the most common CYP2C19 loss-of-
function allele, translating to decreased CYP2C19 enzyme activity, 
with an estimated prevalence of 29% to 35% in Asians and 15% in 
Caucasians and Africans.7 Non-carriers of the *2 allele (homozy-
gous *1/*1) are classified as extensive metabolizers (EMs), carri-
ers of one *2 allele (heterozygous *1/*2) as intermediate metabo-
lizers (IMs) and carriers of two *2 alleles (homozygous *2/*2) as 
poor metabolizers (PMs) of clopidogrel. EMs efficiently metabo-
lize clopidogrel to the active form and show the highest levels of 
platelet inhibition with standard 75 mg clopidogrel dosing, while 
IMs and PMs show decreased inhibition of platelet aggregation.8 
The CYP2C19*2 allele has been associated with reduced active 
clopidogrel metabolites and higher on-clopidogrel platelet reactiv-
ity, leading to a greater risk of adverse cardiovascular events in 
PMs and IMs compared to EMs. The strongest association was 
reported in patients with acute coronary syndrome undergoing PCI 
with stent implantation, where *2 allele carriers had an increased 
risk of stent thrombosis.8,9
In-stent restenosis (ISR) is another well-documented complica-
tion of PCI.10 Although the rate of ISR decreased significantly with 
the use of DES compared to balloon angioplasty and BMS, it still 
persisted as a limiting factor for the long-term benefit of PCI, with 
an approximate rate of 10% in non-complex lesions.2,11–15 ISR de-
velops through different phases involving vascular smooth muscle 
cell migration and proliferation, resulting in neointimal hyperpla-
sia.12,15–19 DES-ISR typically occurs within 6 to 12 months after 
stent deployment,11 causing partial reocclusion of the intervention 
site.20 When manifested clinically as stable angina or ischemia, 
repeat target vessel revascularization is generally required.2,21,22 
Risk factors reported to influence the extent of ISR are lesion fea-
tures, including chronic total occlusion, calcification, bifurcation, 
small vessel diameter and long stenosis; technical factors, namely 
stent material, width, length and location, comorbidities such as 
diabetes mellitus, as well as drug resistance and/or hypersensitiv-
ity.12,15,20,21
Very few studies have investigated the relationship between 
CYP2C19*2 allele carrier status and ISR. Two studies published 
in 2014 demonstrated that the CYP2C19*2 variant allele is a risk 
factor for peripheral and vertebral artery ISR in clopidogrel-treated 
patients.23,24 With respect to coronary ISR, a 2015 case-match study 
in an Iranian patient population indicated that the prevalence of ISR 
during a 1-year period after PCI was higher in patients who were 
carriers of CYP2C19*2; however, the association did not reach sta-
tistical significance.25 In contrast, in a recent study by Ruedlinger 
et al.,26 undertaken in Chilean patients who underwent PCI, non-
carriers of the CYP2C19*2 allele had a higher incidence of ISR.
The objective of this study was to assess the relationship be-
tween CYP2C19*2 allele carrier status and coronary ISR.
Methods
Ethics approval
The study protocol was approved by the University of Malta Re-
search Ethics Committee (19/2013).
Study setting
The study was undertaken at Mater Dei Hospital, an acute general 
hospital in Malta. Patients were recruited from the cardiac cath-
eterization suite at the Department of Cardiology and genotyping 
was carried out at the Molecular Diagnostics Unit of the Depart-
ment of Pathology.
Patient recruitment, sampling and data collection
Patients ≥ 18 years of age, with a history of previous PCI with 
stent deployment and who were scheduled for elective PCI after 
coronary angiogram, were recruited from the cardiac catheteriza-
tion suite at the time of PCI by non-probability sampling over a 
12-month period, between 1 January and 31 December 2014. The 
coronary angiogram report of each patient was perused to iden-
tify patients requiring PCI due to angiography-confirmed ISR and 
those who had no ISR. For patients with angiography-confirmed 
ISR, the date of previous PCI to the restenosed stent was noted to 
establish if less than 1 year had elapsed since the previous PCI and 
if the patients were still on clopidogrel therapy.
After obtaining written informed consent, 5 mL of peripheral 
blood was collected from each patient in a purple-top EDTA vacu-
tainer at the time of recruitment. A validated data collection form de-
veloped for the purpose of the study was completed for each patient 
to collect demographic information, cardiac risk factors, comorbidi-
ties, laboratory investigations and concomitant medications.
CYP2C19*2 genotyping
Genomic DNA was extracted using the QIAamp® DNA Mini Kit 
on the fully automated QIAcube (Qiagen) from 200 µL of the anti-
coagulated whole blood sample obtained at the time of recruitment. 
The TaqMan® (Thermo Fisher Scientific) allelic discrimination as-
say (rs4244285, C_259866767_70), which involves DNA amplifi-
cation and homogeneous solution hybridization using fluorescence 
resonance energy transfer, was used for CYP2C19*2 genotyping 
on the 7500 Applied Biosystems real-time PCR system. Using a 
96-well PCR plate, each well had a final volume of 25 µL consist-
ing of genomic DNA, an allele-specific probe labelled with VIC® 
dye and another labelled with 6FAM™ dye, forward and reverse 
primers and TaqMan® Universal PCR Master Mix. The PCR reac-
tion was performed as an initial denaturation at 95 °C for 10 min-
utes, followed by 50 denaturation cycles at 92 °C for 15 seconds 
and annealing/extension at 60 °C for 90 seconds. Patients were 
genotyped as carriers or non-carriers of the CYP2C19*2 allele.
Statistical analysis
Data was analyzed using IBM SPSS Statistics 24. Distribution 
between patients who presented with coronary angiography-con-
firmed ISR at the time of recruitment and patients with no ISR was 
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tested using the one-way ANOVA test for continuous variables and 
the Pearson’s chi-square test for categorical variables, with a 95% 
confidence interval (CI). Continuous variables were presented as 
mean ±standard deviation, and categorical variables were presented 
as number of patients and percentage (%). The association between 
CYP2C19*2 allele carrier status and incidence of coronary ISR 
within 1 year was assessed with cross-tabulations and the Fisher’s 
exact test and by calculating the odds ratio (OR) with a 95% CI. A 
p-value less than 0.05 was considered statistically significant.
Results
Two hundred and fifty-two (30%) patients out of the total 843 pa-
tients (including first PCI and history of PCI patients) who un-
derwent PCI between 1 January and 31 December 2014 were re-
cruited. Of the 252 patients, 82 (32.5%) had a history of previous 
PCI with stent deployment and were included in the study. Out 
of these 82 patients, 29 (35.4%) were undergoing repeat PCI due 
to angiography-confirmed ISR (Fig. 1). Twenty-five patients had 
DES-ISR, while 4 patients had BMS-ISR. The most commonly af-
fected coronary vessels were the left anterior descending artery (n 
= 9), right coronary artery (n = 7) and saphenous venous graft (n 
= 6). Three patients had ISR in a bifurcation lesion. The character-
istics of the patients with ISR and those with no ISR were similar 
(p > 0.05), except for CYP2C19*2 allele carrier status and renal 
impairment (estimated glomerular filtration rate < 60 mL/min/1.73 
m2), which were significantly higher in the patients with ISR (p 
< 0.05) (Table 1). In 13 (44.8%) of the 29 patients with ISR, the 
restenosed stent was deployed within 1 year and the patients were 
Fig. 1. In-stent restenosis at time of recruitment (N = 82). Abbreviations: ISR, in-stent restenosis; PCI, percutaneous coronary intervention.
Table 1.  Patient characteristics (N = 82)a
ISR, n = 29 No ISR, n = 53 p-value 95% CI
Age 64.83±9.896 64.45±8.915 0.862
Male sex 25 (86.2) 40 (75.5) 0.250
Caucasian ethnicity 28 (96.6) 53 (100) 0.174
Carrier of CYP2C19*2 allele 12 (41.4) 10 (18.9) 0.028*
eGFR <60, as mL/min/1.73m2 12 (41.4) 9 (17.0) 0.016*
Active smoking 7 (24.1) 13 (24.5) 0.967
BMI ≥30b, as kg/m2 18 (64.3) 24 (50.0) 0.226
Hypertension 25 (86.2) 49 (92.4) 0.363
Diabetes mellitus 19 (65.5) 30 (56.6) 0.429
Dyslipidemia 26 (89.7) 50 (94.3) 0.435
≥2 previous PCI 12 (41.4) 19 (35.8) 0.624
>1 vessel stented 10 (34.5) 13 (24.5) 0.337
Previous bypass graft surgery 11 (37.9) 12 (22.6) 0.142
aValues are expressed as number of patients (%), except age which is expressed as mean ±standard deviation; b(%) is out of a total of 28 patients for ISR and out of 48 patients for 
no ISR. *Reaching statistical significance (p < 0.05). Abbreviations: CI, confidence interval; eGFR, estimated glomerular filtration rate; ISR, in-stent restenosis; PCI, percutaneous 
coronary intervention.
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on clopidogrel therapy at the time of repeat PCI (Fig. 1).
Of the 29 patients with ISR, 12 were carriers and 17 were non-
carriers of the CYP2C19*2 allele. Eight (66.7%) of the 12 *2 allele 
carriers had ISR within 1 year and were on clopidogrel therapy at the 
time of repeat PCI. Only 5 (29.4%) out of the 17 non-carriers present-
ed with ISR within 1 year. Although the difference between the two 
proportions (37.3%) is large, the association between CYP2C19*2 
allele carrier status and ISR within 1 year was not statistically sig-
nificant (Fisher’s exact p = 0.067; OR: 4.80, 95% CI: 0.98–23.54, p 
= 0.053) (Table 2).
Discussion
The findings from this study show that despite a higher propor-
tion of CYP2C19*2 allele carriers exhibiting coronary ISR with-
in 1 year compared to non-carriers, and *2 allele carriers being 
4.08-times more likely to exhibit ISR than non-carriers, the asso-
ciation between CYP2C19*2 allele carrier status and development 
of coronary ISR was not statistically significant (p > 0.05). Our 
findings are similar to Nozari et al.25 who reported that the preva-
lence of ISR after PCI was higher in *2 allele carriers but without 
a statistically significant relationship, and contrast to Ruedlinger 
et al.,26 who identified non-carriers of the *2 allele with higher 
incidence of coronary ISR.
According to Mitra and Agrawal,12 the overall pathogenesis of 
ISR is not entirely understood and “prevention of ISR appears to 
be a multipronged attack as no therapeutic magic bullet exists to 
block all the processes in one go”. In clinical practice, the impor-
tance of ISR is well-known.10 Reducing the incidence of ISR is 
crucial, since ISR limits the long-term benefit of PCI by affecting 
the quality of life of the patient due to physical limitations caused 
by angina,26 and augments health care costs due to the need for 
repeat revascularisation.27,28
Stent implantation causes injury to the arterial vessel wall, stimu-
lating platelet activation through a number of pathways,17,29,30 hence 
the rationale for prescribing antiplatelet therapy after PCI. Platelets 
are reported to be involved in the pathophysiology of ISR,12,18,29,30 
so the higher proportion of CYP2C19*2 allele carriers exhibiting 
coronary ISR within 1 year compared to non-carriers may be ex-
plained in terms of inadequate platelet inhibition after PCI when 
these decreased clopidogrel responders are treated with clopidogrel. 
Recommendations for CYP2C19 genotype and clopidogrel therapy 
state that a more potent P2Y12 receptor inhibitor with no or little 
interindividual response variability, such as prasugrel or ticagrelor, 
unless contraindicated, rather than clopidogrel, should be prescribed 
in carriers of the CYP2C19*2 allele, while non-carriers should be 
prescribed clopidogrel at the standard 75 mg dose.8,31
The p-value is highly dependent on the sample size and it is very 
unlikely to obtain statistical significance when the sample size is 
small, unless the difference between the proportions is consider-
able. The Fisher’s exact p-value obtained in our study (0.067) ex-
ceeds the 0.05 level of significance by only a small margin, despite 
the very small sample size (29 patients with ISR). Compared to 
our study, Nozari et al.25 had a larger sample of patients with ISR 
(50 patients) and a higher p-value (0.273) was obtained. Hence, 
given the small sample size, the findings from our study should 
not be ignored. Since the p-value obtained in our study exceeds 
the 0.05 level of significance by only a small margin, it is likely 
that a slightly larger sample size would have yielded a significant 
association between the two categorical variables.
The restricted sample size in this study limited power of the data 
and the ability to draw definite conclusions. Larger prospective 
case-control studies are recommended to further assess this reported 
association, which may open up new possible explanations of the 
pathophysiology of ISR and substantiate the role of CYP2C19*2 
genotyping with respect to antiplatelet therapy in patients undergo-
ing PCI. The possibility that measured and unmeasured clinical and 
angiographic factors that may predispose to ISR development, such 
as lesion features, technical details of the PCI and comorbidities, 
which may have contributed to this association cannot be excluded. 
One measured predisposing factor is renal impairment, which was 
significantly higher in patients with ISR. This association is sup-
ported by other studies that have linked renal insufficiency with in-
creased incidence of coronary ISR.32–36 On the other hand, in a study 
by Best et al.,37 ISR was not increased with chronic kidney disease.
Future research prospective
ISR is a limiting factor for the long-term benefit of PCI. When 
manifested clinically, repeat target vessel revascularization is gen-
erally required. The higher proportion of CYP2C19*2 allele car-
riers exhibiting ISR within 1 year compared to non-carriers is an 
interesting finding regarding the pharmacogenetic implications of 
clopidogrel and the incidence of coronary ISR. Larger prospec-
tive studies are recommended to assess this finding further, which 
may open up new possible explanations of the pathophysiology of 
ISR and support the utilization of CYP2C19*2 genotyping for the 
personalization of antiplatelet therapy in patients undergoing PCI.
Conclusions
The higher proportion of CYP2C19*2 allele carriers exhibiting 
Table 2.  CYP2C19*2 allele carrier status versus ISR within 1 year: Cross-tabulation
ISR within 1 year
Total
Yes No
Carrier of CYP2C19*2 allele
Yes
Number of patients 8 4 12
Percentage 66.7 33.3 100.0
No
Number of patients 5 12 17
Percentage 29.4 70.6 100.0
Total 13 16 29
p = 0.067 (Fisher’s exact 2-sided). Odds ratio: 4.80, 95% confidence interval: 0.98–23.54, p = 0.053.
Abbreviation: ISR, in-stent restenosis.
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ISR within 1 year compared to non-carriers is an interesting find-
ing regarding the association of clopidogrel metabolism and the 
prevalence of coronary ISR. Since no significant association was 
found, which may be attributed to the small sample size, larger 
prospective studies are recommended to further assess this asso-
ciation.
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